

























- prostate cancer. *Nature* 2020;578:306-10.
100. Chen D, Lu T, Yan Z, Lu W, Zhou F, et al. Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins. *Eur J Med Chem* 2019;182:111633.
  101. Rathore R, McCallum JE, Varghese E, Florea AM, Büsselberg D. Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs). *Apoptosis* 2017;22:898-919.
  102. Von Karstedt S, Montinaro A, Walczak H. Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. *Nat Rev Cancer* 2017;17:352-66.
  103. Croft M, Siegel RM. Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases. *Nat Rev Rheumatol* 2017;13:217-33.
  104. Liu X, Yue P, Khuri FR, Sun SY. Decoy receptor 2 (<em>DcR2</em>) is a p53 target gene and regulates chemosensitivity. *Cancer Res* 2005;65:9169-75.
  105. Mansour NM, Bernal GM, Wu L, Crawley CD, Cahill KE, et al. Decoy receptor DcR1 is induced in a p50/Bcl3-dependent manner and attenuates the efficacy of temozolomide. *Cancer Res* 2015;75:2039-48.
  106. Liu X, Yue P, Khuri FR, Sun SY. p53 upregulates death receptor 4 expression through an intronic p53 Binding site. *Cancer Res* 2004;64:5078-83.
  107. Shetty S, Graham BA, Brown JG, Hu X, Vegh-Yarema N, et al. Transcription factor NF- $\kappa$ B differentially regulates death receptor 5 expression involving histone deacetylase 1. *Mol Cell Biol* 2005;25:5404-16.
  108. Woo SM, Seo SU, Min KJ, Kwon TK. BIX-01294 sensitizes renal cancer Caki cells to TRAIL-induced apoptosis through downregulation of survivin expression and upregulation of DR5 expression. *Cell Death Discov* 2018;4:29.
  109. Kim SY, Hong MN, Heo SH, Park S, Kwon TK, et al. Inhibition of euchromatin histone-lysine N-methyltransferase 2 sensitizes breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through reactive oxygen species-mediated activating transcription factor 4-C/EBP homologous protein-de. *Mol Carcinog* 2018;57:1492-506.
  110. Benoit YD, Laursen KB, Witherspoon MS, Lipkin SM, Gudas LJ. Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells. *J Cell Physiol* 2013;228:764-72.
  111. Kasman L, Onicescu G, Voelkel-Johnson C. Histone deacetylase inhibitors restore cell surface expression of the coxsackie adenovirus receptor and enhance CMV promoter activity in castration-resistant prostate cancer cells. *Prostate Cancer* 2012;2012:137163.
  112. Srivastava RK, Kurzrock R, Shankar S. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. *Mol Cancer Ther* 2010;9:3254-66.
  113. Borbone E, Berlingieri MT, De Bellis F, Nebbioso A, Chiappetta G, et al. Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. *Oncogene* 2010;29:105-16.
  114. Nebbioso A, Carafa V, Conte M, Tambaro FP, Ciro A, et al. C-Myc modulation and acetylation is a key HDAC inhibitor target in cancer. *Clin Cancer Res* 2017;23:2542-55.
  115. Zhang B, Liu B, Chen D, Setroikromo R, Haisma HJ, et al. Histone deacetylase inhibitors sensitize TRAIL-induced apoptosis in colon cancer cells. *Cancers (Basel)* 2019;11:645.
  116. Kurt IC, Sur I, Kaya E, Cingoz A, Kazancioglu S, et al. KDM2B, an H3K36-specific demethylase, regulates apoptotic response of GBM cells to TRAIL. *Cell Death Dis* 2017;8:e2897.
  117. Tanaka H, Hoshikawa Y, Oh-hara T, Koike S, Naito M, et al. PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor- $\kappa$ B activation. *Mol Cancer Res* 2009;7:557-69.
  118. Li M, An W, Xu L, Lin Y, Su L, et al. The arginine methyltransferase PRMT5 and PRMT1 distinctly regulate the degradation of anti-apoptotic protein CFLAR L in human lung cancer cells. *J Exp Clin Cancer Res* 2019;38:1-13.
  119. Kauh J, Fan S, Xia M, Yue P, Yang L, et al. C-FLIP degradation mediates sensitization of pancreatic cancer cells to trail-induced apoptosis by the histone deacetylase inhibitor LBH589. *PLoS One* 2010;5:e10376.
  120. Symanowski J, Vogelzang N, Zawel L, Atadja P, Pass H, et al. A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL. *J Thorac Oncol* 2009;4:149-60.
  121. Kerr E, Holohan C, McLaughlin KM, Majkut J, Dolan S, et al. Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis. *Cell Death Differ* 2012;19:1317-27.
  122. Klingbeil O, Lesche R, Gelato KA, Haendler B, Lejeune P. Inhibition of bet bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents. *Cell Death Dis* 2016;7:1-13.
  123. Zhao L, Okhovat JP, Hong EK, Kim YH, Wood GS. Preclinical studies support combined inhibition of BET family proteins and histone deacetylases as epigenetic therapy for cutaneous T-cell lymphoma. *Neoplasia (United States)* 2019;21:82-92.